Skip to content

US · MDGL · BIOTECHNOLOGY

Madrigal Pharmaceuticals, Inc. (MDGL) intrinsic value and stock valuation

$379.10as of 2026-11-21 · Mkt cap 11.88B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Madrigal Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values MDGL with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from MDGL’s statements →

Madrigal Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology West Conshohocken, PA 19428 madrigalpharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$958.4M
20112025
Net income
-$-288.28M
20112025
Free cash flow
-$-190.02M
20112025
Total equity
$602.7M+20.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$958.4M$180.1M$0.00$0.00$0.00
Operating income-$-300.1M-$-497.88M-$-380.5M-$-293.57M-$-242.48M
Net income-$-288.28M-$-465.89M-$-373.63M-$-295.35M-$-241.85M
EPSd-$-12.85M-$-21.9M-$-19.99M-$-17.23M-$-14.62M
Operating cash flow-$-189.55M-$-455.57M-$-324.23M-$-224.86M-$-183.92M
Capital expenditure-$-470K-$-1.46M-$-1.48M-$-220K-$-210K
Free cash flow-$-190.02M-$-457.03M-$-325.71M-$-225.07M-$-184.13M
Total assets$1.26B$1.04B$640.6M$362.6M$273.3M
Total debt$354.4M$119.6M$117.2M$49.9M$800K
Net debt$155.7M$19.6M$17.3M-$-281.66M-$-35.47M
Total equity$602.7M$754.4M$405.3M$197.4M$196.1M
Cash and short-term investments$983.6M$926.3M$634.1M$358.8M$270.4M
Income statement
20252024202320222021
Revenue$958.4M$180.1M$0.00$0.00$0.00
Cost of revenue$56.2M$6.23M$0.00$0.00$0.00
Gross profit$902.3M$173.9M$0.00$0.00$0.00
Research and development expenses$388.5M$236.7M$272.4M$245.4M$205.2M
Selling, general and administrative expenses$813.8M$435.1M$108.2M$48.1M$37.3M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$1.2B$671.8M$380.5M$293.6M$242.5M
Cost and expenses$1.26B$678M$380.5M$293.6M$242.5M
Interest income$37.4M$46.7M$19.6M$2.19M$360K
Interest expense$22.3M$14.7M$12.7M$3.96M$0.00
Depreciation and amortization$1.51M$1.1M$530K$470K$410K
Ebitda-$-264.47M-$-450.12M-$-360.39M-$-290.92M-$-241.44M
Operating income-$-300.1M-$-497.88M-$-380.5M-$-293.57M-$-242.48M
Total other income/expenses, net$11.8M$32M$6.87M-$-1.78M$640K
Income before tax-$-288.28M-$-465.89M-$-373.63M-$-295.35M-$-241.85M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-288.28M-$-465.89M-$-373.63M-$-295.35M-$-241.85M
Weighted average shares outstanding$22.4M$21.3M$18.7M$17.1M$16.5M
Weighted average diluted shares outstanding$22.4M$21.3M$18.7M$17.1M$16.5M
Balance sheet
20252024202320222021
Cash and short-term investments$983.6M$926.3M$634.1M$358.8M$270.4M
Net receivables$134.5M$53.8M$0.00$0.00$0.00
Inventory$74.8M$34.1M$0.00$0.00$0.00
Total current assets$1.25B$1.03B$637.3M$361.4M$271.7M
Property, plant and equipment, net$6.44M$4.59M$3.27M$1.2M$1.65M
Goodwill and intangible assets$7.38M$4.73M$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$13.8M$9.32M$3.27M$1.2M$1.65M
Total assets$1.26B$1.04B$640.6M$362.6M$273.3M
Accounts payable$48.9M$43.6M$28M$23.8M$21.4M
Short-term debt$1.02M$980K$530K$600K$410K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$310.3M$169.3M$118.6M$115.9M$76.8M
Long-term debt$353.3M$118.6M$116.7M$49.3M$390K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$346.6M$118.6M$116.7M$49.3M$390K
Capital lease obligations$6.73M$2M$1.71M$600K$800K
Total liabilities$656.9M$287.9M$235.2M$165.2M$77.2M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-2.09B-$-1.8B-$-1.34B-$-962.66M-$-667.31M
Accumulated other comprehensive income (loss)$870K$470K$470K-$-30K-$-80K
Total equity$602.7M$754.4M$405.3M$197.4M$196.1M
Total investments$784.9M$826.2M$534.2M$27.2M$234.1M
Total debt$354.4M$119.6M$117.2M$49.9M$800K
Net debt$155.7M$19.6M$17.3M-$-281.66M-$-35.47M
Cash flow statement
20252024202320222021
Net income-$-288.28M-$-465.89M-$-373.63M-$-295.35M-$-241.85M
Depreciation and amortization$4.72M$700K$530K$470K$410K
Stock-based compensation$98.1M$79.9M$49.7M$31.6M$26.9M
Change in working capital-$-8.5M-$-72.34M-$-3.28M$37.6M$30.7M
Accounts receivable-$-80.65M-$-53.82M$0.00$0.00$0.00
Inventory-$-36.98M-$-34.07M$0.00$0.00$0.00
Accounts payable$5.28M$15.6M$4.21M$2.45M$20.4M
Net cash provided by operating activities-$-189.55M-$-455.57M-$-324.23M-$-224.86M-$-183.92M
Investments in property, plant and equipment-$-470K-$-1.46M-$-1.48M-$-220K-$-210K
Acquisitions, net$0.00$0.00$0.00-$0.00$790K
Net cash used for investing activities$32.3M-$-274.39M-$-502.52M$206.7M-$-5.05M
Common stock issued$38.1M$397.5M$260.2M$255.4M$170.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$256M$735.1M$595.1M$313.5M$171.2M
Net change in cash$98.8M$5.1M-$-231.63M$295.3M-$-17.73M
Cash at end of period$203.8M$105M$99.9M$331.6M$36.3M
Operating cash flow-$-189.55M-$-455.57M-$-324.23M-$-224.86M-$-183.92M
Capital expenditure-$-470K-$-1.46M-$-1.48M-$-220K-$-210K
Free cash flow-$-190.02M-$-457.03M-$-325.71M-$-225.07M-$-184.13M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Madrigal Pharmaceuticals, Inc.

        Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.

        CEO
        William J. Sibold
        Employees
        915
        Beta
        -1.06

        Explore

        Frequently asked questions

        What is the intrinsic value of Madrigal Pharmaceuticals, Inc. (MDGL)?

        Madrigal Pharmaceuticals, Inc. (MDGL) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MDGL undervalued?

        MDGL trades at a price of $379.10 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.